| NCT ID | NCT06617013 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Duke University |
| Condition | GERD in Children |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2024-10-23 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2024-10-23 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to evaluate the prevalence of gastroesophageal reflux disease (GERD) symptoms in pediatric patients with cystic fibrosis using the Gastroesophageal Symptom Assessment Scale (GSAS) and the impact of stopping anti-GERD therapy on the GERD symptoms reported.
Eligibility Criteria
Inclusion Criteria: * Children 2-18 years of age with a confirmed CF diagnosis by either a positive sweat test or 2 disease causing CFTR mutations. * Signed consent Exclusion Criteria: * Declining to participate in the study or sign consent * History of severe GERD per gastroenterology diagnosis and documentation * GSAS score \>80
Contact & Investigator
Shatha Yousef
PRINCIPAL INVESTIGATOR
Duke University Hospital
Frequently Asked Questions
Who can join the NCT06617013 clinical trial?
This trial is open to participants of all sexes, aged 2 Years or older, up to 18 Years, studying GERD in Children. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06617013 currently recruiting?
Yes, NCT06617013 is actively recruiting participants. Contact the research team at yara.salameh@duke.edu for enrollment information.
Where is the NCT06617013 trial being conducted?
This trial is being conducted at Durham, United States.
Who is sponsoring the NCT06617013 clinical trial?
NCT06617013 is sponsored by Duke University. The principal investigator is Shatha Yousef at Duke University Hospital. The trial plans to enroll 20 participants.